Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost in Systemic Sclerosis (AURORA)
NCT04040322Phase 3Completed
- Sponsor
- CiVi Biopharma
- Start
- Oct 2019
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of iloprost in Raynaud phenomenon, sponsored by CiVi Biopharma. Started Oct 2019; status: completed.
02
Drugs
iloprost
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT04040322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040322.